Early access
Sign in
Not yet taking people in United StatesNo phase

An AI Tool and Chatbot to Help Manage Diabetes and Obesity Medicines

Tests an AI decision tool for dosing incretin mimetic medicines in diabetes or obesity.

Key facts

Who runs it
NYU Langone Health
Where
New York, United StatesSee the site
Trial code
Registry title
AIManage Using an AI-driven CDS and Chatbot
Status
Not yet recruiting
People taking part
16 people, planned
Started
1 Jun 2026
Expected to end
30 Mar 2029
Type of study
Interventional, 2 groups
Treatments tested
  • AIManage
Record updated
22 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for primary or bariatric care providers and for adult patients who take or recently took an incretin mimetic medication (IMM). Patients must speak English or Spanish and agree to text messages.

Age
Patients must be over 18 years old.
Sex
All sexes can join.
Earlier treatment
Patients must take an IMM now or have taken one in the past 6 months. Providers must care for at least 5 patients prescribed an IMM.

Main reasons for not taking part

  • Providers who refuse to take part
  • Patients who refuse or cannot give informed consent

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Provider Eligibility Criteria (Phase 1)
  • Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
  • Provide care to at least 5 patients prescribed an IMM; Patient Eligibility Criteria (Phase 1)
  • (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months
  • Fluency in English or Spanish
  • Be willing to send/receive text messages; and
  • Be > 18 years of age

Who cannot take part

  • Provider Exclusion Criteria (Phase 1) • Refuse to participate
  • Patient Exclusion Criteria (Phase 1)
  • Refuse or are unable to provide informed consent

Where in United States

  • NYU Langone HealthNew York, United StatesContact: Elizabeth Stevens, PhD, MPHNot yet recruiting

About the trial

What the trial wants to find out

The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH.

Read full original descriptionShow less

The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).

The 2 groups in the trial

  • Providers (Phase 1)Treatment being tested

    Providers prescribing IMM for at least 5 adult patients in primary care and obesity medicine clinics.

    Treatment: AIManage

  • Patients (Phase 1)Treatment being tested

    Adult patients prescribed an IMM in the past 6 months.

    Treatment: AIManage

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications
Plain-language title
An AI Tool and Chatbot to Help Manage Diabetes and Obesity MedicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
22 April 2026